Gerald Cagle, PhD, Director, Former Head of R&D, Alcon
Gerald Cagle has served as a member of the Eyevensys board since 2017, and was appointed Chair in January 2020. He worked in research and development for Alcon for more than 30 years and was the company’s senior vice president and chief scientific officer from 1996 to 2009, when he retired. From 2009 until 2013, he held the position of chief operating officer at Cognoptix, a company focused on the diagnosis of Alzheimer disease. Dr Cagle currently serves on the board of directors of Aerie Pharmaceuticals, GrayBug Vision, Nacuity Pharmaceuticals, Inc., and AB2 Bio Ltd. Dr Cagle earned his BS from Wayland College, his MS and PhD from the University of North Texas, and completed the Program for Management Development at Harvard Business School.